Polycystic disease

CCRM FERTILITY WELCOMES REGIONAL DIRECTOR OF CLINICAL REPRODUCTIVE GENETICS, DR. JASMINE ALY, TO JERSEY CITY TEAM

Retrieved on: 
Wednesday, March 27, 2024
ART, WRNMMC, Obstetrics, PCOS, Gynaecology, Obesity, Polycystic disease, Reproductive Sciences, Science, NHGRI, Genetic distance, FACOG, Genetics, COVID-19, Patient, Empathy, Medical genetics, Cooper University Hospital, Research, African Americans, USUHS, Fibroid, Reproduction, Assisted reproductive technology, IRMS, NIH, Polycystic ovary syndrome, Outline of health sciences, Reproductive endocrinology and infertility, Publication, Fertility, REI, Birth control

JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey. Dr. Aly holds the rare distinction of being a triple-specialized physician as an Obstetrician-Gynecologist, Reproductive Endocrinologist, and Medical Geneticist.

Key Points: 
  • JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey.
  • As Regional Director of Clinical Reproductive Genetics, Dr. Aly will bring her expertise to the CCRM Fertility team and aims to leverage her comprehensive fellowship training in genetics to further advance the field and better serve patients.
  • As an esteemed reproductive endocrinologist, she will utilize cutting-edge  technology and innovative scientific techniques to ensure patient success rates continue to rise.
  • "Dr. Aly's expertise in genetics is an invaluable attribute that will redefine care at CCRM | IRMS," notes CCRM Fertility CEO, Bob LaGalia.

HRC Fertility Center Adds Hakman and Wertheimer to Roster of Award-Winning Physicians

Retrieved on: 
Thursday, September 28, 2023
Women, Men, General Health, Health, Family, Baby, Maternity, Consumer, Other Health, Pregnancy, Education, Patient experience, HRC, Davidoff, Woman, Infertility, Intelligence, Research, Millennials, Reproductive endocrinology and infertility, Social media, Generation Z, IVF, Polycystic ovary syndrome, American Board of Commissioners for Foreign Missions, Fertility, Polycystic disease, MD, Patient, PCOS, Hearing, Empathy, Jews, Nursing, Birth control, Medicine

HRC Fertility Center , one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Sasha Hakman, MD and Sahar Wertheimer, MD , to its team of award-winning physicians.

Key Points: 
  • HRC Fertility Center , one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Sasha Hakman, MD and Sahar Wertheimer, MD , to its team of award-winning physicians.
  • Effective immediately, Dr. Hakman and Dr. Wertheimer, both highly sought-after Reproductive Endocrinologist and Infertility Specialists, have joined the center’s West Los Angeles office.
  • Dr. Hakman has a longstanding family and personal history of infertility and Polycystic Ovary Syndrome (PCOS).
  • Dr. Hakman is a subject matter expert for the American Board of OB-GYN, and serves as HRC Fertility’s baby center medical advisor.

OM1 Launches Hidradenitis Suppurativa Dataset to Expand Real-World Evidence in Dermatology

Retrieved on: 
Thursday, September 21, 2023
Other Health, Networks, General Health, Data Management, Mental Health, Technology, Artificial Intelligence, Health Technology, Cardiology, Neurology, Other Technology, Health, Obesity, Skin, Depression, OM1, Anxiety, MBA, FAAD, Polycystic ovary syndrome, HS, Hidradenitis suppurativa, Polycystic disease, HIV disease progression rates, MD, Data, Patient, Conditional sentence, Diagnosis, AI, Mental health, Disease, Geography, Medical imaging, Dermatology

OM1 a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the continued expansion of its Dermatology Network to include Hidradenitis Suppurativa (HS) , a systemic inflammatory disease, enhancing the dataset with almost 26,000 patient records.

Key Points: 
  • OM1 a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the continued expansion of its Dermatology Network to include Hidradenitis Suppurativa (HS) , a systemic inflammatory disease, enhancing the dataset with almost 26,000 patient records.
  • Studies continue to show the link between skin conditions and mental health.
  • With one in four Americans impacted by a skin disease, combined with the increasing mental health epidemic, it’s critical to uncover and introduce solutions that will ultimately improve health outcomes.
  • “People are going years without an accurate diagnosis of their dermatological conditions, resulting in a worsening of both the disease and the patient’s mental health,” said Stefan Weiss, MD, MBA, FAAD Managing Director of Dermatology at OM1.

Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, August 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Columbia University, PD, Senior, Investment, Cohort, DHEAS, CAH, Clinical trial, Infection, Spruce, Pharmacokinetics, Public, Woman, G&A, Polycystic ovary syndrome, POWER, Public expenditure, Public health, Adrenal insufficiency, A4, Polycystic disease, Patient, PCOS, Administration, Adolescence, Androstenedione, Financial toxicity, Regulatory affairs, Research and development, Regulation, R, FDA, Safety, Dehydroepiandrosterone sulfate, Pharmaceutical industry, Nursing, Cryptocurrency, Adult, Quality

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.
  • In our CAHmelia program in adult classic CAH, we’ve surpassed 75% enrollment in the CAHmelia-203 study and are approaching 75% enrollment in the CAHmelia-204 study.
  • Cohort 2 in our CAHptain study for pediatric classic CAH is nearly fully enrolled, with screening in cohort 3 currently underway.
  • Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2023 were $120.5 million.

Rejuvenating Fertility Center Updates Its IVF Plus Program and its Financing Options Amid Inflation

Retrieved on: 
Tuesday, March 7, 2023
Transfer, LendingClub, Ozone, Patient, Freezing, PCOS, Infertility, Hysterosalpingography, Risk, Fertility, Fertilisation, Lipid emulsion, Male, HSG, PRP, RFC, Polycystic disease, Woman, Cryopreservation, ICSI, Platelet-rich plasma, PGT, Diagnosis, Genetic testing, Polycystic ovary syndrome, Family, IVF, STD, Semen analysis, SIS, Pregnancy, FET, Birth control, Mineral oil

The comprehensive IVF treatment program at Rejuvenating Fertility Center covers three cycles to be completed within 9 months from the start of the first cycle.

Key Points: 
  • The comprehensive IVF treatment program at Rejuvenating Fertility Center covers three cycles to be completed within 9 months from the start of the first cycle.
  • With the IVF + Guaranteed Program at RFC, cycle monitoring will be covered when performed at the center.
  • RFC also introduces new financing options in response to inflation:
    CapexMD is known for offering financing options for all types of fertility treatments.
  • Rejuvenating Fertility Center is a medical center specializing in the field of reproductive endocrinology and infertility.

Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Health, Pharmaceutical, Administration, Route of administration, Polycystic ovary syndrome, Brain, NDA, II, Therapy, Neuron, Microglia, Route, Acquisition, News, Clinical trial, Astrocyte, Discovery, Disease, Central nervous system, Birth control, Pharmaceutical industry, Dietary supplement, Polycystic disease

This report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape.
  • A detailed picture of the Polycystic ovarian syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovarian syndrome treatment guidelines.
  • The assessment part of the report embraces, in depth Polycystic ovarian syndrome commercial assessment and clinical assessment of the pipeline products under development.
  • Polycystic ovarian syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Intrauterine Insemination (IUI) Devices Markets, 2023-2027: Advancements in Healthcare Facilities & Rising Awareness and Initiatives by Governments to Bolster Growth

Retrieved on: 
Monday, January 23, 2023
Polycystic ovary syndrome, PCOS, Erectile dysfunction, Artificial insemination, Automation, Catheter, Life, Insemination, ART, Uterus, Union Council of Ministers, Growth, Fertility, AI, IUI, Polycystic disease, United Nations, Hospital, Femtech, Fertilisation, Patient, Woman, Infertility, National Women's Health Network, GE HealthCare, Birth control

The global intrauterine insemination (IUI) devices market is anticipated to observe impressive growth during the forecast period, 2023-2027.

Key Points: 
  • The global intrauterine insemination (IUI) devices market is anticipated to observe impressive growth during the forecast period, 2023-2027.
  • The major factors include rise in infertility rate, and advancements in healthcare facilities are driving the growth of the global intrauterine insemination (IUI) devices market.
  • The Intrauterine Insemination (IUI) is minimally invasive and cost-effective first-line therapy for patients compared to other fertility treatment options.
  • This growing incidences of infertility among the world's population is propelling the Intrauterine Insemination (IUI) Devices market forward.

Global Intrauterine Insemination (IUI) Devices Markets, 2017-2022 & 2023-2027 - United States to Become a Lucrative Market Due to the Rise in Infertility Rates - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 19, 2023
Health, Genetics, Hospital, Catheter, Infertility, Polycystic disease, IUI, GE Healthcare, Artificial insemination, Uterus, AI, Fertilisation, Woman, PCOS, Growth, Patient, Automation, National Women's Health Network, United Nations, Femtech, ART, Life, Insemination, Union Council of Ministers, Fertility, Polycystic ovary syndrome, Erectile dysfunction, Birth control

The global intrauterine insemination (IUI) devices market is anticipated to observe impressive growth during the forecast period, 2023-2027.

Key Points: 
  • The global intrauterine insemination (IUI) devices market is anticipated to observe impressive growth during the forecast period, 2023-2027.
  • The major factors include rise in infertility rate, and advancements in healthcare facilities are driving the growth of the global intrauterine insemination (IUI) devices market.
  • This growing incidences of infertility among the world's population is propelling the Intrauterine Insemination (IUI) Devices market forward.
  • United States is expected to be a lucrative market in the forecast period due to rise in infertility rate in the country.

XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

Retrieved on: 
Tuesday, January 3, 2023
Therapy, Kidney, Research, Patent Cooperation Treaty, Polycystic kidney disease, Laboratory, Risk, Kidney disease, PCT, Patient, Treatment, Polycystic disease, Diagnosis, Patent, Hyperuricemia, Chronic kidney disease, Pharmaceutical industry

This patent is based on key discoveries by XORTX’s independent scientific research partners suggesting that an important diagnostic and therapeutic opportunity exists.

Key Points: 
  • This patent is based on key discoveries by XORTX’s independent scientific research partners suggesting that an important diagnostic and therapeutic opportunity exists.
  • This patent application builds upon new discoveries in polycystic disease and more specifically polycystic kidney disease (“PKD”) and proposes methods of diagnosing the risk associated with aberrant purine metabolism alone, or in combination with hyperuricemia in patients most at risk for accelerated kidney disease progression.
  • Recent discoveries at XORTX and by its independent research laboratories, suggests that certain individuals, most at risk for accelerated kidney disease progression, may be identified, diagnosed, and treated based upon a novel risk profile.
  • This new patent application proposes proprietary diagnostic methods, and potential therapeutic approaches for personalizing the medicines used to treat those most at risk of health consequences of aberrant purine metabolism in cystic kidney diseases.

PCOS Severity Is Linked to Insulin Resistance -- and Gynov Can Help

Retrieved on: 
Thursday, September 29, 2022
PCOS, Health, Incidence, Woman, Insulin resistance, Vaginal bleeding, Plasma protein binding, Infertility, Polycystic ovary syndrome, Polycystic disease, Folliculogenesis, Female, Pathology, Folate, Dietary supplement, Inositol, Gestational diabetes, Birth control, MD

FORT LAUDERDALE, Fla., Sept. 29, 2022 /PRNewswire/ -- PCOS (Polycystic Ovary Syndrome) is a prevalent female health concern. As much as 12% of American women suffer from the condition, and it is one of the most common causes of infertility. While PCOS is something millions of women across the nation struggle with, it's possible to address the issue through a basic study of the root cause — something that the French health company Gynov has been doing for years now.

Key Points: 
  • Gynov has created its groundbreaking product Gynositolas a way to manage the most severe symptoms of PCOS by focusing on a key area: insulin resistance.
  • Studies have shown that the degree of insulin resistance in a woman's body correlates with the severity of their PCOS symptoms specifically the degree of disturbance in their menstrual cyclicity .
  • In other words, if vaginal bleeding is disrupted or irregular, it points to a more severe case of PCOS.
  • "It restores ovarian function, improves oocyte quality, and helps reduce insulin resistance and therefore gestational diabetes incidence and severity."